Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
4.830
+0.130 (2.77%)
May 20, 2026, 4:00 PM EDT - Market closed

Kalaris Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
111193----
Market Cap Growth
23.96%-----
Enterprise Value
6.18108.520000
Last Close Price
4.838.44----
PB Ratio
1.672.45----
P/TBV Ratio
1.421.64----
Debt / Equity Ratio
0.480.42-1.020.110.130.10
Net Debt / Equity Ratio
-0.93-1.07-0.52-1.07-0.88-0.97
Net Debt / EBITDA Ratio
1.341.83-0.970.791.161.29
Net Debt / FCF Ratio
1.502.19-2.421.261.402.05
Quick Ratio
12.0312.150.076.499.616.56
Current Ratio
12.1912.230.116.619.996.69
Return on Equity (ROE)
-59.85%-308.10%-145.36%-102.85%-75.02%-59.47%
Return on Assets (ROA)
-41.14%-72.17%-52.53%-85.39%-60.65%-51.97%
Return on Invested Capital (ROIC)
-672.85%-1698.01%1471.54%-2451.00%-942.92%-2139.91%
Return on Capital Employed (ROCE)
-44.57%-98.74%-71.91%-96.30%-68.28%-55.93%
Buyback Yield / Dilution
-176.07%0.00%-237.47%-35.75%-22.10%-133.41%
Total Shareholder Return
-176.07%0.00%-237.47%-35.75%-22.10%-133.41%
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q